Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Turnstone Biologics
Deal Size : Undisclosed
Deal Type : Acquisition
Turnstone Biologics Acquires Novel Cell Therapy Platform Developer, Myst Therapeutics
Details : Turnstone gains full access to this technology, the complete R&D capabilities of Myst along with existing development collaborations, and a pipeline of tumor infiltrating lymphocyte programs with the lead candidate expected to enter the clinic this year.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 20, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Turnstone Biologics
Deal Size : Undisclosed
Deal Type : Acquisition